AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17508190
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vs 12.5 mg hyperbaric 0.5% levobupivacaine
Trial: 16371677
Drug: Schoolwide intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Schoolwide intervention that incorporated universal and targeted treatment
Trial: 8555131
Drug: One single
RxNorm normalized name: Risperidone Single-Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single pre‐operative dose of metronidazole (10 mg/kg)
Trial: 8555131
Drug: Both metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both metronidazole (20 mg/kg) and cefuroxime (50 mg/kg) in a single preoperative dose
Trial: 8555131
Drug: Preoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotics (metronidazole and cefuroxime)
Trial: 1975490
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine injections as needed
Trial: 7150
Drug: Gallamine triethiodide
RxNorm normalized name: Gallamine Triethiodide
DrugBank: Gallamine triethiodide (DB00483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallamine triethiodide (40 mg)
Trial: 31869726
Drug: G1: 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1: 24 sets of five repetitions with 30 s rest at 80% of one repetition maximum using Iowa Oral Performance Instrument (IOPI) per day
Trial: 31869726
Drug: G2: Forceful
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G2: Forceful swallow of 5 mL of water in a neutral posture every 10 s for 20 min per day
Trial: 31869726
Drug: G3: 5
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: G3: 5 mL of water swallowing exercise in chin-down posture every 10 s for 20 min per day
Trial: 17891897
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 200 mg administered at specified times during Days 2-4
Trial: 11161370
Drug: DepoCyte 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoCyte 50 mg injected once every 2 weeks for one month of induction therapy
Trial: 11161370
Drug: DepoCyte 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoCyte 50 mg
Trial: 9002389
Drug: White light
RxNorm normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White light treatment for 2 weeks
Trial: 9002389
Drug: Placebo red
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo red light treatment for 2 weeks
Trial: 7989947
Drug: Chemotherapy response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy response
Trial: 28544687
Drug: Local physiotherapy
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local physiotherapy and oral nonsteroidal anti‐inflammatory drugs
Trial: 27869712
Drug: Pterocarpan-high soybean
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pterocarpan-high soybean leaf extract (PT) 2 g/day for 12 weeks
Trial: 27869712
Drug: Placebo (starch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch, 3 g/day) for 12 weeks
Trial: 20679774
Drug: L-BIS group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BIS group (BIS values 20-30)
Trial: 20679774
Drug: L-BIS group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-BIS group
Trial: 12439209
Drug: Single-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nevirapine (NVP)
Trial: 16052084
Drug: Maternal CD4
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal CD4 cell count < 500 x 10(6) cells/l
Trial: 16052084
Drug: Maternal viral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal viral load > 50 000 copies/ml
Trial: 2021986
Drug: Epidural nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural nalbuphine (0.075-0.3 mg.kg-1)
Trial: 2021986
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (0.1 mg.kg-1)
Trial: 6177846
Drug: Naldecon (antihistamine-decongestant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldecon (antihistamine-decongestant)
Trial: 25233654
Drug: Fire needling
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire needling therapy
Trial: 25233654
Drug: Oxycycline tablets
RxNorm normalized name: Doxycycline Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycycline tablets (100 mg, twice daily for 20 days) with external application of adapalene gel before sleep
Trial: 25233654
Drug: Oxycycline tablets
RxNorm normalized name: Doxycycline Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycycline tablets
Trial: 22608570
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCSs), more than 2 courses per year
Trial: 22608570
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCSs), less than or equal to 2 courses per year
Trial: 22608570
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCSs)
Trial: 20807066
Drug: Single-dose, immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose, immediate-release dexmethylphenidate (dMPH)
Trial: 12637133
Drug: Pharmacokinetic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic dosing (n=43)
Trial: 12637133
Drug: Fixed once‐daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed once‐daily dosing (n=38)
Trial: 10982163
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate supplement alone (750 mg daily)
Trial: 10982163
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate plus calcitriol (750 mg calcium carbonate + 0.5 microg calcitriol daily)
Trial: 1480877
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug given once daily
Trial: 6198064
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (120 mg/m2, monthly) combined with vinblastine and bleomycin
Trial: 6198064
Drug: Low-dose cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cisplatin (15 mg/m2, daily X 5 monthly) combined with vinblastine and bleomycin
Trial: 27427235
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogens (CEE) daily for 28 days
Trial: 22327404
Drug: Lipid/heparin emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid/heparin emulsion (Intralipid) infusion
Trial: 22327404
Drug: Heparin only
RxNorm normalized name: Heparin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin only infusion
Trial: 16139778
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored behavioral medicine intervention
Trial: 11966744
Drug: Lyndiol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyndiol (2.5 mg lynestrenol + 0.05 mg ethinyl‐oestradiol)
Trial: 11966744
Drug: Pill-free period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill-free period
Trial: 7558212
Drug: Intraumbilical oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraumbilical oxytocin (10 units in 20 ml saline)
Trial: 7558212
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oxytocin infusion 10 units in 250 ml of dextrose saline at 125 ml/hr)
Trial: 2288128
Drug: Preoperative Co
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative Co 60 gamma teletherapy (part of combined treatment)
Trial: 6789851
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate dry powder inhalation (20 mg/dose)
Trial: 6789851
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose aerosol (2 mg/dose)
Trial: 28714728
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus no CM
Trial: 23267373
Drug: Medical intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical intervention (fluticason nasal spray and oral Pseudoephedrin)
Trial: 17403076
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg (PPI group)
Trial: 17403076
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg (H2RA group)
Trial: 15110132
Drug: Rofecoxib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (25 mg) once daily for 7 days
Trial: 15110132
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg) once daily for 7 days
Trial: 15110132
Drug: Meloxicam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (7.5 mg) once daily for 7 days
Trial: 9855324
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once/day for 14 days
Trial: 9855324
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice/day for 14 days
Trial: 3184885
Drug: Marijuana-laced brownies
RxNorm normalized name: Lilium brownii var. viridulum bulb extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana-laced brownies (1.6 g of marijuana plant material, 2.8% THC)
Trial: 28588109
Drug: Supervised progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised progressive exercise therapy (ET)
Trial: 25205534
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose INR self-control (VLO group)
Trial: 25205534
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose INR self-control (VLT group)
Trial: 25205534
Drug: Low-dose INR
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose INR self-control (LOW group)
Trial: 15570231
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine infusion at a rate of 6 mL/h
Trial: 7494801
Drug: CR tablet
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR tablet A (acetaminophen A)
Trial: 7494801
Drug: CR tablet
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR tablet B (acetaminophen B)
Trial: 7494801
Drug: Both CR
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both CR tablets A and B
Trial: 31955525
Drug: Anti-EGFR antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-EGFR antibody plus chemotherapy
Trial: 31290518
Drug: SC‐FOS‐B (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC‐FOS‐B (combination of spent coffee grounds and fructooligosaccharides)
Trial: 11123737
Drug: Sublingual morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual morphine 0.1 mg x kg(‐1)
Trial: 11123737
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 0.1 mg x kg(‐1)
Trial: 9882058
Drug: Flamazine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flamazine treatment (standard silver sulfadiazine cream)
Trial: 2465709
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg hydromorphone with 1/200,000 epinephrine (N = 15)
Trial: 2465709
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg hydromorphone alone (N = 15)
Trial: 31856912
Drug: Irinotecan dose-escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan dose-escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib
Trial: 31856912
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg regorafenib alone
Trial: 25557853
Drug: Duloxetine 40
RxNorm normalized name: duloxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 40 mg once a day for a month
Trial: 25557853
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg once a day for a month
Trial: 24176253
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First with Assertive Community Treatment (HF-ACT)
Trial: 17225705
Drug: Multimodality approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality approach including radiotherapy, chemotherapy, and palliative care for advanced non-small cell carcinoma
Trial: 17225705
Drug: Chemotherapy (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (combined with radiotherapy for limited disease) for small cell carcinoma
Trial: 55532
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of salbutamol
Trial: 9778003
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of salbutamol and intravenous lidocaine
Trial: 7980747
Drug: Empirical H2-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empirical H2-blocker treatment (group 2)
Trial: 3136677
Drug: alfentanil 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 500 micrograms and midazolam 5 mg
Trial: 31238011
Drug: High-sodium meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium meal (HSM; 1495 mg Na+)
Trial: 31238011
Drug: Low-sodium meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium meal (LSM; 138 mg Na+)
Trial: 25909681
Drug: Fenspiride (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride (80 mg thrice daily)
Trial: 25909681
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibacterial preparations, topical decongestants, glucocorticoids)
Trial: 21888757
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 μg once daily for 2 weeks
Trial: 17607120
Drug: Docetaxel 35
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 35 mg/m2 IV on days 1, 8, and 15, and cisplatin 80 mg/m2 IV on day 15, every 4 weeks for four cycles
Trial: 17607120
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 IV plus cisplatin 80 mg/m2 IV on day 1 every 3 weeks for four cycles
Trial: 9866064
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg aspirin from day 2 of the cycle through pregnancy testing
Trial: 9866064
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (Control)
Trial: 7637874
Drug: Yohimbine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (alpha 2-adrenergic antagonist)
Trial: 7637874
Drug: Morphine (postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (postoperative intravenous)
Trial: 183943
Drug: Propranolol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (180 and 360 mg daily)
Trial: 27185571
Drug: QGE031 (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 (240 mg every 2 weeks for 10 weeks)
Trial: 16037180
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of 1.5% lidocaine containing 15 mug of epinephrine IV
Trial: 10759733
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic cream (containing lignocaine and prilocaine) followed by local anaesthetic infiltration
Trial: 8613046
Drug: Methotrexate (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (12.5 mg once weekly for 9 months)
Trial: 1358484
Drug: Subcutaneous bolus
RxNorm normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bolus injections of 100 micrograms octreotide every 8 hours
Trial: 1358484
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of the same daily dose of octreotide
Trial: 1358484
Drug: Both bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both bolus and continuous infusion treatment
Trial: 4013628
Drug: Intercostal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal block (i.c.b.) and centrally acting analgesics on demand
Trial: 4013628
Drug: Age-dependent analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-dependent analgesic demand
Trial: 4013628
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of treatment with centrally acting analgesics
Trial: 27820648
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of traditional Chinese medicine and Western medicine
Trial: 17224178
Drug: Daily injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily injectable recombinant GH for 9 months
Trial: 16125525
Drug: Fluvastatin (Flu)
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin (Flu) administered for 6 weeks
Trial: 12163783
Drug: C1-inhibitor intravenously
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor intravenously in a 1-hr infusion, starting with 6000 IU, followed by 3000 IU, 2000 IU, and 1000 IU at 12-hr intervals
Trial: 10357404
Drug: Combined paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combined paclitaxel (50 mg/m2/dose), cisplatin (15 mg/m2/dose), and etoposide (40 mg/m2/dose) administered twice weekly for 3 weeks, repeated every 28 days.
Trial: 10357404
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with or without concomitant 5-fluorouracil after chemotherapy.
Trial: 8951506
Drug: Leflunomide therapy
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide therapy
Trial: 6189695
Drug: L-tryptophan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (4 g)
Trial: 30902911
Drug: Transversus thoracis
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus thoracis muscle plane (TTP) block with 20 mL of either 0.3% or 0.5% ropivacaine bilaterally
Trial: 30902911
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (control group, no injections)
Trial: 30394494
Drug: Therapeutic hypothermia
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic hypothermia (cold therapy with local sterile frozen ice compress)
Trial: 22113535
Drug: Nutraceutical-Combined Pill
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical-Combined Pill (berberine 500 mg, policosanol 10 mg, red yeast rice 200 mg, folic acid 0.2 mg, coenzyme Q10 2.0 mg, astaxanthin 0.5 mg)
Trial: 20017910
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (10 mg of ezetimibe plus 160 mg of fenofibrate)